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Background: Macrophage-colony stimulating factor (M-CSF) has been implicated in HIV neuropathogenesis
through its ability to modulate activation of macrophages (MΦs) and microglia, as well as enhance the
susceptibility of these cells to infection and promote virus production. We have recently reported that MΦs
accumulating perivascularly and within nodular lesions in archival brain tissue of simian immunodeficiency virus
(SIV)-infected rhesus macaques with encephalitis (SIVE) express M-CSF. In contrast, IL-34, which shares the same
receptor, cFMS, was observed more often in parenchymal cells.
Methods: Frontal white and grey matter from non-infected and SIV-infected rhesus macaques with and without
SIVE were examined by single- and double-label immunohistochemistry for M-CSF, IL-34, and CD163 expression.
Primary rhesus macaque and human peripheral blood mononuclear cells were cultured with and without 2.5 ng/
ml M-CSF or IL-34 alone and with 470 nM or 4.7 μM of GW2580, a receptor tyrosine kinase inhibitor with high
specificity for cFMS. After 24 h, cells were analyzed by flow cytometry to examine the effect of these cytokines on
promoting an M2 monocyte/MΦ phenotype.
Results: Here, we demonstrate that in SIVE brain, accumulating M-CSF+ MΦs are also CD163+, while IL-34 does not
appear to co-localize significantly with CD163 in the parenchyma. We further demonstrate that M-CSF and IL-34 are
expressed by neurons in normal brain but are altered in SIV and SIVE. Through in vitro studies, we show that M-CSF
and IL-34 upregulate CD163, a marker for type 2 activation of MΦs (M2), by primary monocytes, which is attenuated
by the addition of GW2580.
Conclusions: Together, these data suggest that both cFMS ligands may promote and/or prolong M2 activation of
MΦs and microglia in brains of SIV-infected animals with encephalitis. As such, cFMS signaling may be an attractive
target for eliminating long-lived MΦ reservoirs of HIV infection in brain, as well as other tissues.
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Microglia and macrophages (MΦs) found within compart-
ments associated with the central nervous system (CNS),
such as perivascular MΦs, are essential to fighting off for-
eign pathogens, as well as maintaining CNS homeostasis.
Injury to the CNS results in rapid activation of microglia
and CNS-associated MΦs, which upregulate numerous
cell-surface and soluble factors that trigger or amplify
innate and acquired immune responses. The type, degree,* Correspondence: tlfsmith@temple.edu
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unless otherwise stated.and length of the microglial/MΦ response to injury can
determine whether they are neuroprotective or contribute
to neurodegeneration (for review, see Amor et al. [1]).
In addition to their pro-inflammatory functions and
role in coordinating an adaptive immune response, tis-
sue MΦs, including microglia, are involved in resolv-
ing inflammation and tissue remodeling and repair. To
perform these varied functions, MΦ activation is con-
siderably plastic and heterogeneous, broadly classified
into two primary subclasses of classical (M1) and al-
ternative (M2) activation, based on distinct functional
and phenotypic characteristics (for review, see Liu et al.ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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inflammatory M1 MΦs secrete interleukin (IL)-12 and
support T helper (TH)1 cell responses [4]. In contrast,
alternatively activated, anti-inflammatory M2 MΦs secrete
IL-10, suppress TH1 function, and stimulate TH2 cell pro-
duction [5,6]. A balance between classical and alternative
activation is necessary for appropriate immune function
and in a healthy immune response, MΦs are believed to
rapidly shift from one activation state to another in
response to external stimuli [7].
Although M2 MΦs are often considered ‘favorable’
due to their role in resolving inflammation, inducing
tolerance, and promoting wound healing [6,8,9], an in-
crease in the frequency of M2-polarized MΦs is believed
to have injurious results associated with their transcrip-
tional output in many chronic inflammatory conditions,
including rheumatoid arthritis, atherosclerosis, and
obesity [10-13]. In addition, extensive or prolonged M2
polarization may contribute to disease pathogenesis by
weakening host immunity. For example, soluble factors
produced by tumor-associated MΦs, which are reported
to express markers consistent with M2-polarization [14],
contribute to the impaired immune surveillance seen
within the glioma microenvironment [15]. In neuroin-
flammatory disease, alternatively activated MΦs may be
a continued source of reactive oxygen species (ROS) in
the brain, which are necessary for conversion to M2
activation [16].
Many individuals with human immunodeficiency virus
(HIV) infection develop varying degrees of cognitive im-
pairment, collectively termed HIV-associated neurocog-
nitive disorders (HAND). Although the pathogenesis of
HAND is not completely understood, activated microglia
and infiltrating MΦs into the CNS are believed to play a
prominent role in its development and/or progression
(for review, see Hong and Banks [17]). Recently, we
reported mild-to-moderate accumulation of CD163+
perivascular MΦs and microglia in autopsy brain from
anti-retroviral treated-HIV-infected persons without
encephalitis, although to a much lesser degree than that
seen in HIV encephalitis (HIVE), a histopathological
correlate of the most severe form of HAND, HIV-
associated dementia (HIV-D) [18]. This observation, as
well as other indications of neuroinflammation in all
HIV+ cases studied, suggests that chronic neuroinflam-
mation, even in the absence of productive infection in
the brain, is a common feature of HIV and likely con-
tributes to all degrees of HAND.
Expression of CD163 has been used to phenotypically
identify a subclass of M2 MΦs [19-22] (for review, see
Moestrup and Møller [23]), suggesting that the observed
CD163+ MΦs and microglia in brain are M2 activated/
polarized. The inciting factor(s) of MΦ polarization in the
context of HIV infection, however, is/are unknown. Aleading candidate molecule in M2 polarization of MΦs
in HIV infection is macrophage-colony stimulating
factor (M-CSF). M-CSF has been shown in cerebro-
spinal fluid (CSF) of HIV-infected patients [24,25] and
is believed to support virus production and disease
progression (for review, see Haine et al. [26]). We re-
cently identified the MΦs accumulating perivascularly
and within nodular lesions as the principal source of
M-CSF in simian immunodeficiency virus (SIV)-in-
fected rhesus macaques, a relevant animal model for
HIV-associated neuropathogenesis [27], with encephal-
itis (SIVE). In this same study, we found expression of
IL-34, which shares the same receptor, cFMS, but
appeared to have a greater association with cells in the
parenchyma, rather than those accumulating perivas-
cularly and within nodular lesions [27].
To further characterize these cells and explore the
potential relationship of M-CSF and/or IL-34 with
M2 activation, we performed immunohistochemical
analyses of brain tissue from non-infected and SIV-
infected rhesus macaques, with and without encephal-
itis (SIVE), to investigate the association between
CD163 expression with M-CSF and IL-34. Here, we
report that the CD163+ MΦs that accumulate perivas-
cularly and within nodular lesions and serve as the
primary reservoir of productive SIV and HIV infection
in the CNS [28,29], also appear to be the primary
source of M-CSF in SIVE. In contrast, CD163 expres-
sion in the parenchyma does not co-localize consider-
ably with M-CSF, but does with IL-34. In addition,
neurons also express M-CSF and IL-34, which is al-
tered in SIV infection, suggesting a potential mechan-
ism by which neurons communicate with neighboring
microglia. Finally, our in vitro studies of rhesus ma-
caque and human peripheral blood mononuclear cells
(PBMC) demonstrate that cFMS signaling via either of
its ligands may contribute to sustained M2 activation
in brain in SIV infection and SIVE.
Methods
Immunohistochemistry
Sections from archival frontal lobe brain tissue (4 μm) of
eight SIVmac251 infected and two non-infected rhesus
macaques were kindly provided by Dr. Jay Rappaport. Sec-
tions include both frontal white matter (FWM) and frontal
grey matter (FGM). Four of the eight SIV-infected animals
had SIVE, characterized by the presence of perivascular
cuffs, nodular lesions, and multinucleated giant cells,
which are histological hallmarks of both HIV and SIV en-
cephalitis [30-33]. Immunohistochemistry was performed
as described by us previously [28,34,35]. Briefly, deparaffi-
nized and rehydrated 4-μm brain tissue sections under-
went high heat non-enzymatic antigen retrieval, followed
by blocking with 20% normal goat (Lampire Biological
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Waltham, USA) serum and overnight incubation with pri-
mary mouse monoclonal CD163 (1:100; Vector Laborator-
ies, Burlingame, USA), M-CSF (1:12.5; Novus Biologicals,
Littleton, USA) or rabbit polyclonal IL-34 (1:200; Abcam,
New Territories, Hong Kong) antibodies. The spleen from
non-infected rhesus macaques was used as a positive con-
trol. Negative controls consisted of isotype antibodies used
in place of the primary and tissues incubated in buffer
without primary antibody. Antigen-specific staining was
detected with goat-α-rabbit or horse-α-mouse biotinylated
antibodies (Vector Laboratories), followed by Vectastain
ABC Alkaline Phosphatase and Vector Red Alkaline
Phosphatase Substrate Kit (Vector Laboratories), accord-
ing to the manufacturer’s instructions. Tyramide sig-
nal amplification (Perkin Elmer, Waltham, USA) was
used for CD163 and IL-34 detection, according to the
manufacturer’s instructions. Following a light counter-
stain with hematoxylin, sections were dehydrated in xy-
lenes, coverslipped with Permount, and analyzed under
light microscopy. Immunohistochemistry for each antigen
of interest was performed in a single run for all animals/
groupings.
Immunohistochemistry quantification
Quantification of single-label CD163, M-CSF, and IL-34
expression in brain among the three test animal group-
ings was completed using a bioquantification software
system (Bioquant Image Analysis Program). A total of
12 ×20, microscopic fields of 0.31 mm2 each were
assessed per brain section using a microscope (Nikon,
Tokyo, Japan) with a motorized x, y stage and a digital
camera (Q-Imaging Retiga, Surrey, Canada) that were
linked to a computer with the software program. An un-
biased quantification approach was used, with a random
start, and then systematic sampling of 12 adjacent (non-
overlapping) sites within the brain region of interest
using the motorized stage option. Analysis conditions
were retained across animals/groupings for each antigen
of interest by white-balancing the camera prior to data
acquisition and maintaining the same light intensity of
the microscope for each slide. The Videocount Area
Array and color thresholding options of the Bioquant
software were utilized for these measurements, as previ-
ously defined in detail [36]. Briefly, videocount (VC) area
is defined as the number of pixels in a field that meet a
user-defined color threshold of staining. The user-
defined color threshold of immunostaining for each anti-
gen (that is, positivity of each antigen) was defined by
setting the red-green-blue values to detect the range of
positive signal values for a particular immunostained
antigen, while excluding color ranges of other antigens
and background noise. The threshold values for each
antigen were stored in the computer program andmaintained for each immunohistochemical analysis
across all animals and groupings. The inclusion of posi-
tive cells and exclusion of potential background noise
was verified by viewing the image of positive area pro-
jected onto the computer screen. Inappropriate inclu-
sions/exclusions were corrected manually. The percent
positivity for each field and antigen was determined by
dividing the number of positive pixels (those that
matched the defined color threshold) by the total num-
ber of pixels within the VC area, which were multiplied
by 100. Data are expressed as the percentage of antigen
positivity per 0.31 mm2 field. The assessment was carried
out in a blinded fashion.
Isolation of PBMC and cell culture
Whole blood from two non-infected, healthy rhesus ma-
caques was acquired from Bioqual, Rockville, MD, USA, in
accordance with Bioqual Institutional Animal Care and Use
Committee protocol #14-3027-56. Buffy coat from a
de-identified human volunteer was acquired from Bio-
logical Specialty Corporation in Colmar, PA, USA. The
Biological Specialty Corporation is an FDA-licensed
facility (US license #856) and abides by all applicable
federal and state regulations concerning the collection
and distribution of whole blood and blood products.
PBMC were isolated by density gradient from heparin-
ized blood or buffy coat using ACCUSPIN Tubes
(Sigma, St. Louis, USA) containing Histopaque-1077
(Sigma). Viable PBMC were plated at 5 × 106 cells/ml
in Costar 24-well cell culture plates (Corning, Tewksbury,
USA) and maintained in RPMI 1640 with L-glutamate
(ThermoScientific, Waltham, USA) supplemented with
penicillin/streptomycin (Cellgro, Manassas, USA) and
2% FBS. PBMC were maintained at 37°C and 5%
CO2 for 24 h in media with and without 2.5 ng/ml
recombinant human (rh)M-CSF (R&D, Minneapolis,
USA) or rhIL-34 (R&D) and with and without 4.7 μM or
470nM GW2580 (Calbiochem, Billerica, USA). Brefeldin
A (eBioscience, San Diego, USA) was added to each
well 6 h prior to harvest. PBMC were harvested and
washed with FACS Wash (FW; Hanks’ Balanced Salt
Solution (ThermoScientific), 3% normal horse serum (NHS)
(ThermoScientific), 0.02% sodium azide (Fisher)) and pre-
pared for flow cytometric analysis.
Flow cytometric analyses
Flow cytometric analyses were performed on cultured
human and rhesus macaque PBMC, using fluorochrome-
conjugated antibodies, CD14-PCP-Cy5.5 (M5E2, BD, Franklin
Lakes, USA), CD163-PE (Mac2-158; Trillium Diagnostics,
Maine, USA), CD16-Pacific Blue (3G8, BD), and IL-10-
APC (JES3-19 F1, BD) as described previously [37]. The
antibody-fluorochrome panel was designed according to op-
timized detection and required information. Isotype controls
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specificity of each antibody in the panel. Fluorescence minus
one (FMO) tests and non-stained PBMC were used for gat-
ing. For each test, 30,000 events were collected on a
4-laser 13-color LSRII Analyzer (BD) and analyzed
using FlowJo version 10.0.7r2 (TreeStar, Ashland). Fol-
lowing identification of single events and live/dead dis-
crimination using a Live/Dead Fixable Blue Dead Cell
Stain Kit (Invitrogen, Grand Island, USA), monocytes
were defined within a broad gate, based on forward
scatter (FSC) and side scatter (SSC) properties. Identi-
fication of monocytes was further refined by expres-
sion of CD14, a lipopolysaccharide (LPS) receptor
routinely used as a lineage marker for monocytes.
CD14+ monocytes are the parent population for all
monocyte populations/subsets described in this manu-
script. Representative dot plots demonstrate gating
strategies used in identifying the CD14+ parent popu-
lation and specific monocyte subsets under the differ-
ent treatment conditions (Figure 1).
Statistical analyses
The frequencies of CD163+, M-CSF+, and IL-34+ popu-
lations in brain and the percent frequencies of M-CSF+
and IL-34+ monocyte (CD14+) populations from the
in vitro studies were compared using ordinary and re-
peated measures one-way ANOVA with Tukey’s multiple
comparisons post-test. Pearson correlations were per-
formed to evaluate potential relationships between
monocyte subsets investigated in the in vitro studies, as
well as the results from the bioquantification of antigens
of interest identified by immunohistochemistry in brain
tissues. Statistical analyses were performed using Prism
6 for Mac OS X (GraphPad Software, version 6.0d).
P values ≤0.05 were considered statistically significant.
Results
The frequency of CD163+ brain MΦs/microglia is
increased in SIVE
As others and we have shown previously, considerable
accumulation of CD163+ MΦs and microglia is seen in
SIVE brain [35,38-40] (Figure 2). In the brain of non-
infected animals, CD163 expression is largely limited to
the perivascular MΦ, with little to no immunopositivity
detected in the parenchymal white matter (Figure 2A,
D). Infrequent areas of CD163 expression are seen in the
parenchymal white matter in SIV infection (Figure 2B);
however, this appears to be considerably less than that
observed in SIVE (Figure 2C). Likewise, a slight accumu-
lation of CD163+ perivascular MΦs is seen in SIV-
infected animals without encephalitis (Figure 2E), as
compared to non-infected animals (Figure 2D), but with-
out the significant cuffing characteristic of SIVE
(Figure 2F). In addition to CD163 expression by MΦsaccumulating perivascularly in SIVE brain, MΦs com-
prising nodular lesions are also CD163+ (Figure 2G).
Although microglial expression of CD163 is seen in the
parenchymal white matter in SIV infection without en-
cephalitis, it does appear to be greater in SIVE. To deter-
mine the extent of parenchymal CD163 expression in SIV
and SIVE, we utilized a bioquantification software system
to quantify parenchymal CD163 positivity in cerebral
white matter of non-infected and SIV-infected rhesus ma-
caques, with and without encephalitis, excluding perivas-
cular cuffs and nodular lesions in SIVE. This reveals an
overall marked accumulation of CD163+ MΦs and micro-
glia in SIVE, as compared to the SIV without encephalitis
and non-infected groupings (Figure 2H). It does not reach
statistical significance, however, presumably due to the
small number of animals in the study and the presence of
a single outlier in each of the SIV+ and SIVE groupings.
M-CSF, but not IL-34, expression is associated with CD163+
MΦs that accumulate perivascularly and within nodular
lesions in SIVE
Recently, we reported that both known ligands for
cFMS, M-CSF and IL-34, are expressed in white matter
of non-infected and SIV-infected rhesus macaques [27].
These studies showed that while IL-34 expression
remained unchanged in cerebral white matter, irrespect-
ive of SIV infection or the development of SIVE, M-CSF
expression appeared to be decreased by parenchymal
cells in SIV and SIVE, but with significant expression by
cells accumulating perivascularly and within nodular
lesions in SIVE brain [27]. IL-34 also appeared to be
expressed by some cells in these areas of pathology but
to a markedly lesser degree than M-CSF [27]. To further
characterize the IL-34 and M-CSF expressing cells in
SIVE, we explored a potential relationship between M-
CSF and/or IL-34 expression with CD163+ MΦs/micro-
glia through double-label immunohistochemistry studies.
These studies reveal little co-localization of CD163
(Figure 3A) and M-CSF (Figure 3B) in the parenchymal
white matter (Figure 3C); however, M-CSF does appear
to be produced by other CD163− cells (Figure 3C). In
contrast, significant co-localization of CD163 with
M-CSF is seen in cells that accumulate perivascularly
and within nodular lesions (Figure 3F,I).
In contrast to M-CSF, some CD163+ parenchymal
microglia appear to express IL-34 in SIVE (Figure 4A,B,
C). Additionally, numerous glia, not positive for CD163,
also appear to express IL-34 (Figure 4C). While IL-34
expression is seen in MΦs/microglia in the vicinity of
perivascular cuffs (Figure 4E), it is not seen to a great
extent by cells that comprise the cuffs, themselves
(Figure 4F). As compared to cuffs, IL-34 is more highly
expressed within nodular lesions (Figure 4H); however,
little overlap with CD163 is seen (Figure 4I).
Figure 1 CD14+ back gating and dot plots of monocyte populations. (A) Backgating of CD14+ population shows singlet isolation,
identification of viable population, and forward and side scatter properties of parent population. CD14+ monocytes are the parent population for
all monocyte populations/subsets described in this manuscript. (B) Representative dot plots demonstrate gating strategies used in identifying
specific monocyte subsets under the different treatment conditions.
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brain, which is altered with SIV infection
In addition to M-CSF and IL-34 expression by cells in
cerebral white matter, neurons also express both cytokines
in brain of non-infected (Figure 5A,D), as well as SIV-
infected rhesus macaques without and with encephalitis
(Figure 5B,C,E,F). Bioquantification of neuronal M-CSF
expression revealed that it is significantly decreased in SIV
infection, with an even greater reduction seen in those
with encephalitis (Figure 5G). In contrast, bioquantifica-
tion of IL-34 expression by neurons shows an overallincrease in expression by animals with SIVE (Figure 5H),
as compared to those without encephalitis and non-
infected animals; however, this does not reach statistical
significance in this small study.
cFMS signaling alters CD16+CD163+ monocyte frequency
in vitro
Previous studies have demonstrated that M-CSF pro-
motes expression of CD16 by monocytes in vitro [41,42],
which as we have shown co-localizes markedly with
CD163 by perivascular MΦs and parenchymal microglia
Figure 2 CD163 is upregulated in brain of SIV-infected rhesus macaques with and without encephalitis (SIVE). In the frontal white matter
(FWM) of seronegative animals, CD163 detection (red) is limited to perivascular MΦs (D). CD163+ perivascular MΦs are more frequently observed
in SIV-infected animals (E), with substantial perivascular cuffing of CD163+ MΦs in those with encephalitis (F). In contrast to seronegative animals,
few CD163+ cells are seen within the white matter parenchyma of animals with SIV infection but without encephalitis (A). In rare SIV cases,
infrequent areas in white matter show CD163+ microglia, many appearing to be in an activated state with thickened, retracted processes (B). In
SIVE, the number of parenchymal CD163+ cells greatly increases and appear to be highly activated (C). Prominent accumulation of CD163+ cells
is also observed within nodular lesions in SIVE (G). All panels are shown under oil immersion at × 400 magnification. Bioquantification of
parenchymal CD163+ MΦs/microglia reveals an increase in these cells in FWM of the majority of the animals that developed SIVE, as compared to
seronegative and SIV infected animals without encephalitis (H). Data points represent the average percent of parenchymal CD163 expression per
animal of immunohistochemical staining in twelve randomly selected 0.31 mm2 fields of brain tissue from two seronegative (•), four SIV+ (■), and
four SIVE (▲) animals. Perivascular cuffs and nodular lesions were excluded from quantification.
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to understand the mechanisms driving CD16+CD163+
expression by MΦs and microglia in HIVE and SIVE, we
examined the effect of M-CSF and IL-34, which also
exerts its biological effects through the same M-CSF
receptor, cFMS receptor tyrosine kinase, on rhesus
macaque and human monocyte subset frequencies
in vitro. PBMC, isolated from whole blood of two non-
infected, healthy rhesus macaques and one human buffy
coat, were cultured in complete RPMI containing 2%
FBS and supplemented with 2.5 ng/ml M-CSF or IL-34
with and without GW2580, a tyrosine kinase inhibitor
(TKI) reported to have high specificity for their shared
receptor, cFMS. After 24 h, harvested cells were analyzed
by flow cytometry for alterations in CD16 and CD163
expressing monocyte subsets (Figure 1). These studies
demonstrated no effect of M-CSF exposure on CD163+
or CD16+CD163+ rhesus macaque monocyte (CD14+)
frequency, as compared to those without M-CSFtreatment (Figure 6A). Interestingly, PBMC cultured in
the presence of M-CSF and the cFMS inhibitor,
GW2580, did show a decrease in the frequency of both
monocyte subsets that reached statistical significance for
the CD163+ population (Figure 6A). Although it is
unclear what may have influenced the monocyte subset
frequencies in non-treated cultures, the finding that
inhibiting cFMS signaling reduces these frequencies sup-
ports a role for cFMS in their expansion. No influence
on IL-10 expression was observed with M-CSF exposure
or cFMS inhibition (Figure 6A).
In contrast to M-CSF, IL-34 treatment of rhesus ma-
caque PBMC did increase both the CD163+ and CD16+
CD163+ monocyte subset frequencies, but these increases
did not reach statistical significance (Figure 6B). Like M-
CSF, the IL-10+ monocyte frequency remained unchanged
with IL-34 exposure (Figure 6B).
In vitro studies utilizing human PBMC showed that
both cytokines increased the frequency of CD163+
Figure 3 Accumulating perivascular and nodular CD163+ MΦs/microglia are a major source of M-CSF in SIVE. Parenchymal CD163+
microglia (A) do not appear to express M-CSF in white matter (C); however, M-CSF is produced by other glia (B). Significant co-localization of
CD163 (D, G) and M-CSF (E, H) is seen within perivascular cuffs and nodular lesions (F, I) and appears to be the principal source of M-CSF in
SIVE brain.
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to cells cultured without cytokine supplementation
(Figure 7). Due to a greater number of PBMC recov-
ered from the human buffy coat than the rhesus ma-
caques, we investigated two different concentrations
of GW2580 for its ability to counter these phenotypic
alterations exerted on monocytes by M-CSF and IL-
34. Both concentrations were able to effectively re-
duce the frequency of CD163+ and CD16+CD163+
monocytes cultured in the presence of either cytokine
(Figure 7A,B), strongly supporting the notion that
cFMS signaling promotes CD163 and CD16 expres-
sion. Although CD16 and CD163 expression by
M-CSF treated monocytes is markedly changed with
treatment or cFMS inhibition, statistical significance
is not reached due to variability seen among cultures,
which were performed in triplicate. In contrast, statis-
tical significance is seen with IL-34 treatment and
likely reflects the higher affinity IL-34 has for cFMS[43]. Although, like the rhesus macaque PBMC stud-
ies, no difference in IL-10+ monocyte subset fre-
quency was seen with M-CSF treatment, a small, but
statistically significant increase in this population was
observed with IL-34 treatment (Figure 7B).
The frequency of IL-34 expanded CD163+ monocytes
correlates with IL-10+ monocytes in vitro
Because a small but statistically significant increase in
the IL-10+ monocyte subset frequency was observed
with IL-34 treatment, additional statistical analyses were
employed to investigate potential relationships between
IL-10+ monocyte subset frequencies and the frequencies
of other monocyte subsets of interest. Pearson’s correla-
tions revealed a fairly strong correlation between the fre-
quencies of CD163+ and IL-10+ monocytes (Figure 8A).
This relationship remains significant when further
fractionated into CD163+ monocytes that also express
CD16 (Figure 8C), but not when compared to CD16+
Figure 4 Parenchymal CD163+ microglia, but not perivascular or nodular CD163+ MΦs, express IL-34 in FWM of rhesus macaques with
SIVE. In white matter, CD163+ microglia (A), as well as other glia (B), express IL-34 (C). IL-34 expression appears to be limited to cells within the
vicinity of perivascular cuffs (E), as CD163+ MΦs that accumulate perivascularly (D) do not appear to express appreciable levels of IL-34 (F). In
contrast to perivascular cuffs, IL-34 is more highly expressed within nodular lesions (H). These lesions are comprised largely of CD163+ MΦs (G),
however, little overlap with IL-34 is observed (I).
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expression (Figure 8B).Discussion
In earlier work, we found that the CD163+ MΦs that ac-
cumulate perivascularly and within nodular lesions also
appear to be the principal reservoir of productive HIV
infection in the brain [28]. More recently, we reported
that the principal source of M-CSF in SIVE are the MΦs
that accumulate perivascularly and within nodular
lesions [27]. Here, we demonstrate that these MΦs are
also CD163+. We previously suggested that the MΦs/
microglia that accumulate perivascularly and within
nodular lesions in HIV have recently entered the CNS
from the peripheral blood [28,44]. As such, peripheral
blood monocytes/MΦs may be the major source of M-
CSF in the brain in HIV infection, which is elevated in
CSF of individuals with HIV infection and impaired
cognition [24,25].The role of M-CSF in HIV infection and associated
CNS disease is unclear. Here, we demonstrate that
M-CSF and IL-34, which is also expressed in brain and
shares the same receptor, cFMS, promotes expansion of
the CD16+CD163+ monocyte subset. Inhibiting cFMS
signaling with a small molecule TKI with high specificity
for cFMS attenuates this expansion. These CD16+CD163+
monocytes are phenotypically similar to monocytes we
find expanded in circulation of viremic HIV-infected
persons [34]. Moreover, they are similar to MΦs/micro-
glia that accumulate in the brain of patients with HIV
infection with and without encephalitis [18,28,34,35]. Al-
though co-localization of CD16 and CD163 is observed
on both parenchymal microglia and MΦs comprising
perivascular cuffs and nodular lesions, it is the peri-
vascular and nodular MΦs that appear to be the pri-
mary reservoir of productive virus in the brain
[28,35]. Interestingly, MΦs accumulating in these re-
gions are also the principal source of M-CSF in SIVE
brain. In vitro studies have demonstrated M-CSF
Figure 5 Normal neuronal M-CSF and IL-34 expression is altered in SIV and SIVE. Cells with neuronal morphology in frontal grey matter
(FGM) of rhesus macaques express M-CSF (A, B, C; red) and IL-34 (D, E, F; red), regardless of the presence of SIV infection. Panels are shown at
×400 under oil. Bioquantification analyses reveal neuronal M-CSF expression is significantly decreased in brain of SIV-infected animals, with
(P = 0.0026) and without (P = 0.0085) encephalitis, as compared to seronegative controls (G). In contrast to M-CSF, IL-34 quantification suggests an
increase in neuronal IL-34 expression in animals with SIVE, as compared to seronegative and SIV-infected animals (H); however, this did not reach
statistical significance in this small study. Data points represent the average percent expression per animal of immunohistochemical staining in
twelve randomly selected 0.31 mm2 fields of brain tissue from two seronegative (•), four SIV+ (■), and four SIVE (▲) animals.
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and promotes virus replication [45-47]. In turn, HIV
infection of MΦs promotes production of M-CSF
[45], constituting a positive feedback loop that sup-
ports HIV production/infection. In addition to its nat-
ural role as a key factor in MΦ survival, M-CSF may
serve as a key factor in the development of MΦs as a
long-lived cellular reservoir of HIV/SIV infection. To-
gether, these findings support a pathological role for
M-CSF in both the development and establishment of
tissue reservoirs of HIV-infected MΦs.
M-CSF may also contribute to the development and
maintenance of tissue reservoirs, as well as neuropatho-
genesis, by enhancing migration of monocytes/MΦs,
some of which may be infected, into the brain. In sup-
port of this hypothesis, we previously reported that
the MΦs comprising perivascular cuffs and nodular
lesions also express markers that suggest recent entry
from the peripheral blood into the CNS compartment
[28,34]. M-CSF has been shown to stimulate monocyte
migration in vitro and in vivo, which is mediated
through the association of PI3K with phosphorylated
Y721 of the activated receptor, cFMS [48,49]. En-
hanced CD163 expression may also contribute to the
invasiveness of these cells, as CD163 has been shown
to augment monocyte adherence to LPS or cytokine-
stimulated endothelial cells [50].
M-CSF expression is also seen in CD163− cells in the
parenchymal white matter, although this appears to be lessthan that expressed by cells within perivascular cuffs and
nodular lesions. These cells have not yet been identified,
but may be identified as microglia that do not express
CD163 or express it below the level of detection in
this study. Alternatively, these may be astrocytes, as
murine astrocytes have been demonstrated to express
M-CSF in vitro when stimulated with IL-1 or TNFα
[51], cytokines elevated in CSF and brain in HIV infec-
tion and believed to contribute to HIV-associated
neurological impairment [52-54].
In contrast to M-CSF, IL-34 glial expression appears
to be largely limited to parenchymal microglia, rather
than perivascular and nodular MΦs in SIVE. Addition-
ally, IL-34 expression is largely unchanged from that
observed in brain of non-infected animals and those
with SIV infection but without encephalitis [27], sug-
gesting a spatial relationship between the two cyto-
kines in brain and, presumably, different biological
roles. In support of this notion, we find that both M-
CSF and IL-34 are normally expressed by neurons,
however, while neuronal M-CSF expression is decreased
in SIVE, IL-34 may be increased.
Although M-CSF and IL-34 appear to have some
shared roles, differences have been reported in signal-
ing kinetics and function [43] and may exert different
biological effects in response to foreign pathogens in
the brain and/or maintaining brain homeostasis. IL-34
is highly expressed in brain and is a key regulator in
neuronal progenitor and microglial maturation in the
Figure 6 cFMS inhibition alters the frequency of CD16+CD163+ rhesus macaque monocytes in vitro. An increase in the frequency of
CD163+ and CD16+CD163+ was observed with IL-34 (B) but not M-CSF treatment (A), as compared to PBMC cultured in the presence of media
only. Interestingly, the frequencies of these monocyte subsets were reduced by the addition of the tyrosine kinase inhibitor (TKI), GW2580, which
may reflect inhibition of endogenous M-CSF and/or IL-34 activity in the culture. The frequency of IL-10+ monocytes was high, regardless
of treatment.
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survival of these cells. Systemic administration of M-
CSF or IL-34 in a mouse model of kainic acid-induced
neurotoxicity showed a reduction in neuronal loss that
appears to be a direct result of neuronal cFMS signal-
ing [57]. In addition, activation of astrocytes and
microglia also appears to be attenuated in response to
M-CSF or IL-34 administration in this model [57].
This may be the result of reduced neurotoxicity, itself,
affecting gliosis and/or may be a direct affect of these
cytokines on astrocytes and/or microglia. In support of
this notion, IL-34 treatment of microglia in vitro
promotes expression of the anti-inflammatory factor,
tumor growth factor-β (TGF-β) [58]. It is feasible that
both mechanisms contribute to neuroprotection. Assuch, upregulation of IL-34 by injured or stressed neu-
rons in SIVE may be a mechanism by which neurons
promote self-protection through autocrine IL-34 sig-
naling, as well as by communicating to neighboring
microglia to reduce inflammatory factors that would
promote activation of surrounding glia and advance
damage to neurons. Interestingly, our in vitro studies
of human PBMC showed a small but statistically sig-
nificant increase in IL-10 expression by monocytes.
Although additional studies are needed to assess the
potential biological relevance of this finding, the fre-
quency of CD163+ monocytes correlates strongly with
the frequency of monocytes positive for IL-10. If these
cells are also a rich source of IL-10 in the brain, their
continued presence throughout the disease process
Figure 7 M-CSF and IL-34 increase the frequency of CD16+CD163+ human monocytes in vitro, which is reversed by inhibition of cFMS
signaling. An increase in the frequency of CD163+ and CD16+CD163+ monocytes is observed with both M-CSF (A) and IL-34 (B) but only reaches
statistical significance with IL-34 treatment (B). This may reflect the reportedly high affinity IL-34 has for cFMS, suggested by decreased standard
deviation seen among replicates treated with IL-34, as compared to those treated with M-CSF. The increased frequencies of these monocyte
subsets are abrogated by the addition of GW2580, which restores the frequencies to percentages at or near those seen in PBMC cultured in
media only. The frequency of IL-10+ monocytes is high, regardless of treatment; however, a small but statistically significant increase is seen
with IL-34.
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involves an immunosuppressive environment in the
CNS that is tolerant of HIV/SIV and opportunistic
pathogens, while contributing to neuropathogenesis
through chronic inflammatory activation. The signifi-
cant variability of neuronal IL-34 expression in SIV-
infected animals without encephalitis may reflect other
pro- or anti-inflammatory factors not investigated in
this study.
Conclusions
Tissue MΦs are increasingly recognized as an important
reservoir of viral persistence in HIV infection. In thebrain, infected MΦs and microglia pose additional
concerns due to the presence of virus and viral proteins,
as well as chronic inflammation in the CNS, all of which
contribute to the development and progression of HIV-
associated neurocognitive impairment. Here, we demon-
strate substantial M-CSF expression by CD163+ MΦs
that accumulate perivascularly and within nodular le-
sions in SIVE, suggesting a role for M-CSF in the devel-
opment and maintenance of long-lived viral MΦ/
microglial reservoirs in the brain, as well as supporting
M2 activation of perivascular MΦs and microglia. In
contrast to M-CSF expression in brain, glial IL-34 ex-
pression appears to be unchanged between healthy and
Figure 8 The frequency of IL-10+ monocytes correlates with increased frequencies of specific monocyte subsets when treated in vitro
with IL-34. Increased frequencies of CD163+ (A) and CD16+CD163+ (C) monocyte subsets were found to correlate significantly with IL-10+
monocyte frequencies. The most significant relationship with IL-10+ monocytes was seen with the frequency of CD163+ monocytes, with
approximately 58% of the data points falling within the correlation. This is in agreement with the notion that CD163 expression phenotypically
defines M2 activation of monocytes/MΦs. The frequencies of CD16+ (B) monocytes do not correlate with IL-10+ monocyte frequencies.
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actually increased in those with SIVE. As such, both cy-
tokines may contribute to this MΦ/microglial pheno-
type, which is consistent with M2 MΦ activation.
The role of neuronal IL-34 is not clear; however, it ap-
pears to be an important factor in the developing brain
[59], possibly through supporting neuronal survival. In
recent work, Luo et al. demonstrated that systemic ad-
ministration of either cFMS ligand is neuroprotective in
a transgenic mouse model of Alzheimer’s disease [57].
As neurons, astrocytes, oligodendrocytes, and microglia
may all express the receptor, cFMS [57,60,61], it is un-
clear if this is a direct and/or indirect effect of M-CSF
and/or IL-34 on neurons. Here, we find that while neur-
onal IL-34 is significantly increased in SIVE as compared
to non-infected animals and those with SIV but without
encephalitis, neuronal M-CSF expression progressivelydecreases in SIV and SIVE. Together, these findings of
IL-34 and M-CSF expression in the brain support the
idea of at least some distinct functions between the two
cytokines, as well as a spatial relationship that is comple-
mentary, rather than competitive (Figure 9).
While additional studies are needed to elucidate
the potentially divergent roles of M-CSF and IL-34 in
HIV-associated neurodegenerative disease, these stud-
ies suggest that cFMS signaling through ligation of
M-CSF plays an important role in its pathogenesis. IL-34
may also contribute to M2 activation/polarization in the
brain but may also promote neuronal survival. Advancing
our current understanding of the role of these partially
redundant cytokines in brain health and disease will aid in
the development of targeted therapeutic strategies aimed
at eliminating MΦ reservoirs of HIV infection in the brain
and other tissues.
Figure 9 M-CSF and IL-34 reportedly exert different biological effects on monocyte/MΦs. The limited studies comparing M-CSF and IL-34
in parallel report differences in signaling, function, and location of expression. IL-34 appears to be the dominant cFMS ligand in tissues (left, blue
MΦ) [56,59], where expression of M-CSF is associated more strongly with the peripheral blood and bone marrow (right, red monocyte) [62]. Upon
ligation of cFMS, both cytokines phosphorylate the same intracellular tyrosine residues [43,59]; however, IL-34-mediated phosphorylation (wedge)
may occur more rapidly than that mediated by M-CSF (isosceles triangle) [43]. Further, IL-34 signaling appears to decay more quickly [43] but
stimulates more receptors, as compared to M-CSF [43], with the exception of Y809, which may be favored by IL-34 [43]. Following activation of
second messengers, IL-34-induced signal transduction has been reported to more strongly activate the mitogen-activated protein kinases but has
a weaker effect on the ribosomal S6 kinases than M-CSF [43]. Both ligands participate in chemokine-mediated chemotaxis of monocytes/MΦs
through upregulation of different mediators. IL-34 upregulates C-C chemokine receptor type 2 (CCR2) by primary human monocytes [63], and
M-CSF promotes expression of its ligand, chemokine (C-C motif) ligand 2 (CCL2) [43]. Additionally, IL-34, but not M-CSF, promotes production of
CCL11 [43], while the adhesion molecule, CD54, is upregulated by primary human monocytes more strongly by M-CSF [63]. Functionally, M-CSF,
more than IL-34, promotes migration and supports proliferation in murine myeloid cell lines [43]. IL-34, however, promotes greater expression of
HLA-DR [43] and may play a greater role in promoting cell-mediated immunity. In the context of productive HIV infection, both IL-34 and M-CSF
promote virus production but are greater in the presence of IL-34 [43]. Together, these limited findings suggest that both cFMS ligands promote
distinct populations of myeloid cells that potentially have shared, as well as specialized functions specific to M-CSF or IL-34 stimulation.
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